

News Release

Lonza Group Ltd
Muenchensteinerstrasse 38
CH-4002 Basel, Switzerland
www.lonza.com

Lonza closes acquisition of amaxa

Basel, 3 July 2008 - Lonza Group (SWX:LONN) announces that it has completed the acquisition of amaxa as of 2 July 2008. The transaction was announced at the end of May 2008.

The acquisition of amaxa is in line with Lonza's strategy of growing its life-sciences platform. amaxa is a premium supplier to the cell discovery market with leading edge, proprietary technologies in well defined market niches of transfection systems. The deal further strengthens Lonza's position as a worldwide leader in cell discovery by integrating this unique, proprietary technology into its portfolio and by continuing to develop the company's activities.

Commencing today, Lonza will start integrating amaxa and its approximately 160 employees into the existing structure of the company.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2007, Lonza had sales of CHF 2.87 billion. Further information can be found at www.lonza.com.

About amaxa

As a globally active leader in transfection technologies, amaxa is dedicated to enhancing the speed and quality of basic and pharmaceutical research in gene transfer, gene silencing, and gene-based medicine. amaxa's Nucleofector[®] Technology provides the first efficient non-viral method for the transfer of DNA or siRNA directly into the nucleus of primary cells and hard-to-transfect cell lines. Based on electroporation, Nucleofection[®] utilizes novel and unique electrical parameters generated by a special Nucleofector[®] Device. These are combined with different, cell type specific reagents. amaxa is the worldwide market leader in the segment of primary cell transfection. Founded in 1998, amaxa is located in Cologne, Germany, and in Gaithersburg, MD, USA, and currently employs 160 people. The company's research team is one of the largest R&D groups working on non-viral gene transfer. For more information please visit www.amaxa.com.

For further Information:

Lonza:

Head Corporate Communications

Janet White

Tel +41 61 316 8566

Fax +41 61 316 9566

janet.white@lonza.com

Media Relations

Dominik Werner

Tel +41 61 316 8798

Fax +41 61 316 9798

dominik.werner@lonza.com

Investor Relations

Alexandre Pasini

Tel +41 61 316 8835

Fax +41 61 316 9835

alexandre.pasini@lonza.com

Lonza Acquisition of Amaxa – Frequently Asked Questions

When did Lonza acquire Amaxa?

The acquisition was completed on 2 July, 2008

Who is now the owner?

Lonza

Why is the Amaxa name still here?

Lonza, for the time being is running Amaxa under the current and well recognized name. A name change is anticipated – timelines are currently open.

Who is Amaxa?

As a globally active leader in transfection technologies, Amaxa is dedicated to enhancing the speed and quality of basic and pharmaceutical research in gene transfer, gene silencing, and gene-based medicine. Amaxa's Nucleofector[®] Technology provides the first efficient non-viral method for the transfer of DNA or siRNA directly into the nucleus of primary cells and hard-to-transfect cell lines. Based on electroporation, Nucleofection[®] utilizes novel and unique electrical parameters generated by a special Nucleofector[®] Device. These are combined with different, cell type specific reagents. Amaxa is the worldwide market leader in the segment of primary cell transfection. The company, which was founded in 1998, is located in Cologne (Germany) and in Gaithersburg, MD (USA) and employs 160 people.

Who is Lonza?

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. With a team of over 8,000 professionals and 27 production and R&D sites worldwide, Lonza's products and services span customer needs from research to final product manufacture. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research products, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2007, Lonza had sales of CHF 2.87 billion.

Why did Lonza acquire Amaxa?

Amaxa will significantly strengthen the Cell Discovery business of Lonza Bioscience by complementing and expanding the existing portfolio. Amaxa offers high-end nucleic acid transfection systems and consumables to academic institutions, pharmaceutical and biotechnology businesses. The company provides a leading and unique platform called Nucleofector[®] Technology, which addresses critical industry needs in Cell Discovery. Amaxa's Nucleofector[®] Technology is a transfection method which enables efficient and reproducible transfer of nucleic acids such as DNA or RNA into cells that are considered difficult or even impossible to transfect. Customers will get now the full service from one supplier (transfection of primary cells (Amaxa) and primary cells (Lonza)). The synergistic effect of this transaction has the benefit of one-stop-shop for you as our customer.

Why did Amaxa choose to be acquired by Lonza?

Lonza's and Amaxa's Cell Discovery business are complementary, serving a similar customer base. While Lonza is the leader in the production of primary cells, Amaxa is the leader in the transfection of primary cells. Amaxa will therefore significantly strengthen the Cell Discovery business of Lonza Bioscience by complementing and expanding the existing portfolio. Customers can now get all their primary cell tools through one company.

What does the acquisition mean for Amaxa customers, partners, and distributors?

For the time being, Amaxa customers, partners, and distributors should not expect to see any significant impact resulting from the acquisition by Lonza. Customers should continue to contact their Amaxa Sales Representative or Customer Service team with any questions regarding accounts or orders.

What will happen to the Amaxa brand?

For the time being, Amaxa's business will continue to operate under its current and well recognized name. The Amaxa name carries a lot of value, so despite the fact that the Amaxa offering will be integrated into the Lonza Cell Discovery business, the strong Amaxa brand name will remain associated with the Nucleofector[®] product offering.

What are Amaxa's products?

Amaxa provides cutting edge transfection tools to the research and drug development markets. The company has been establishing itself as the international market leader in high-end applications for the non-viral delivery of nucleic acids and the transfer of other substrates into cells.

What are Lonza's products?

Lonza Bioscience provides primary cells and media, stem cells and media, bioassays, classic and serum free cell culture media and reagents, electrophoresis products, single use cell culture bags and containers along with a contract manufacturing.

Can I purchase Lonza products at Amaxa (Amaxa products at Lonza)

No, until further notice, ordering Amaxa or Lonza products is only possible through the corresponding company channels.

Is my Amaxa quotation number still valid?

Yes. If your quotation is close to its expiration date, please contact your Amaxa Sales Representative.

Will my Amaxa customer number change?

No. Your Amaxa account number will not change at this time. If you are a new customer, please contact the Amaxa Customer Service Team to set up an account.

Where can I purchase Amaxa products from now on?

Amaxa Customers should continue to purchase products through normal channels. Products may be ordered by email, fax or mail:

USA/Canada order.nucleofectionUS@lonza.com
Fax 888-632-9112
amaxa Inc.
205 Perry Parkway, Suite 7
Gaithersburg, MD 20877
U.S.A.

Europe / Rest of World order.nucleofection@lonza.com
Fax: +49-221-99199-599
amaxa AG
Nattermannallee 1
50829 Koeln
Germany

Customers outside of the USA and Europe should continue to contact their distributor to place orders. For the most up-to-date information on distributors of Amaxa products visit www.amaxa.com.

Payments of invoices should continue to be made to Amaxa. For the most up-to-date information on distributors of Amaxa brand products, visit www.amaxa.com.

Where can I purchase Lonza products from now on?

Products may be ordered via phone, fax or online:

USA Phone 800-638-8174 or 301-898-7025
Fax 301-845-8338
Online www.lonza.com (see Online Catalog)

Europe Phone +32 (0) 87 321 611
Fax +32 (0) 87 351 967
Online www.lonza.com (see Online Catalog)

Customers outside of the USA and Europe should contact their local distributor to place orders. For the most up-to-date information on distributors of Lonza products visit www.lonza.com.

Who do I contact for support of Amaxa products?

You can contact our support team via email, phone and fax:

USA/Canada scientific-support.nucleofectionUS@lonza.com
Phone: 888-632-9110 (toll-free)
Fax: 888-632-9112 (toll-free)

Europe / Rest of World scientific-support.nucleofection@lonza.com
Phone: +49-221-99199-400
Fax: +49-221-99199-499

Who do I contact for support of Lonza products?

You can contact our support team via email, phone and fax:

USA biotechserv@lonza.com
Phone: 800-521-0390 or 301-898-7025
Fax 301-845-8338

Europe

techsup.europe@lonza.com

Phone: 32 (0) 87 321 611

Fax: 32 (0) 87 351 967

Where should customers go for information on Amaxa products?

The Amaxa website, www.amaxa.com, has up-to-date product information and pricing.

Where should customers go for information on Lonza products?

The Lonza website, www.lonza.com, has up-to-date product information.

Both web-sites will be joined soon.